Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract, including the esophagus, stomach, liver, biliary system, pancreas, bowels, and anus.
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma.
Alterations in four main genes are responsible for how long patients survive with pancreatic cancer, according to a new study in JAMA Oncology.
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent.
For patients with colorectal cancer that has metastasized to the liver, having a primary tumor on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.
A new study, to be presented at the ESMO 19th World Congress on Gastrointestinal Cancer, shows that so-called "liquid biopsies", blood tests that detect circulating tumour DNA (ctDNA), may not only sound an early alert that a treatment's effect is diminishing, but may also help explain why -sometimes offering clues about what to do next.
The benefits of a "Mediterranean diet" (MD) are well-known when it comes to colorectal protection, but it's hard to know specifically what elements of the diet are the healthiest.
Younger colon cancer patients appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, say researchers at Georgetown Lombardi Comprehensive Cancer Center.
UT Southwestern Medical Center researchers found in a recent phase one clinical trial that stereotactic partial breast radiation was as safe as traditional radiation but decreased treatment time from six weeks to just days.
10x Genomics, a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced publication of an article in the journal Nature of a collaborative research study with researchers at the Stanford University School of Medicine.
Blood tests that could detect cancer before it develops show promise for the future of screening and prevention, though researchers continue to test which cancer clues are good markers for diagnosis.
Walking or jogging helps patients with advanced gastrointestinal cancer to cope better with the side effects of chemotherapy.
A chemical found in tumors may help stop tumor growth, according to a new study.
A new study provides some of the strongest evidence to date that microorganisms living in the large intestine can serve as a link between diet and certain types of colorectal cancer, the lead authors at Dana-Farber Cancer Institute and Massachusetts General Hospital report.
The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU in 2017, a study has found.
Great question – the answer is actually unknown. Every month, there are publications that report on new cancer-related genes, so it's an area of great knowledge growth at the moment.
Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC).
Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.